Welcome to our dedicated page for MBX Biosciences news (Ticker: MBX), a resource for investors and traders seeking the latest updates and insights on MBX Biosciences stock.
MBX Biosciences, Inc. (Nasdaq: MBX) is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, and its news flow reflects progress across multiple clinical programs and corporate initiatives. Company press releases and investor updates highlight developments from its proprietary Precision Endocrine Peptide™ (PEP™) platform, including clinical data, trial milestones, and financing activities.
News for MBX often centers on its lead candidates canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291. Coverage includes topline and follow-up results from the Phase 2 Avail™ trial of once-weekly canvuparatide in chronic hypoparathyroidism, initiation and progress of the Phase 2a STEADI™ trial of imapextide for post-bariatric hypoglycemia, and design and enrollment updates for the Phase 1 trial of MBX 4291 as a GLP-1/GIP co-agonist prodrug for obesity. MBX also issues releases on expected data readouts, planned regulatory interactions, and preparation for Phase 3 development.
Investors following MBX news will also see announcements related to public equity offerings, cash runway disclosures, and participation in major healthcare and investor conferences such as the J.P. Morgan Healthcare Conference and various cardiometabolic and obesity-focused forums. These items provide context on how the company funds its pipeline and communicates its strategy to the market.
This news page aggregates such updates so readers can track MBX’s clinical milestones, pipeline expansion in obesity, and key regulatory and financing events in one place. For those monitoring MBX stock or the broader endocrine and metabolic drug development space, the feed offers an organized view of how the company reports its progress over time.
MBX Biosciences (Nasdaq: MBX) announced an inducement equity award for new Chief Business Officer Karen Basbaum on April 3, 2026. The grant is for 130,000 non-qualified stock options with an exercise price of $32.29, equal to the Nasdaq closing price on April 1, 2026.
The options carry a 10-year term and vest over four years (25% on the one-year anniversary of March 9, 2026, then monthly over three years), and were approved under Nasdaq Listing Rule 5635(c)(4).
MBX Biosciences (Nasdaq: MBX) reported Q4 and full-year 2025 results and clinical progress on March 12, 2026. Key clinical milestones include an FDA End-of-Phase 2 meeting and a Phase 3 start for once-weekly canvuparatide on track for Q3 2026, plus obesity candidate nominations in Q2–Q3 2026.
Pro forma cash and investments totaled $459.1 million as of Dec 31, 2025, expected to fund operations into 2029; 2025 net loss was $87.0 million.
MBX Biosciences (Nasdaq: MBX) appointed Karen Basbaum as Chief Business Officer effective March 10, 2026. Ms. Basbaum brings 20+ years in corporate strategy and business development, including leadership on partnerships and transactions totaling over $10 billion in potential value and roles tied to significant industry M&A.
The hire is positioned to advance MBX’s precision peptide pipeline and to pursue strategic partnerships, financings, and transactions to accelerate development and commercialization of therapies for endocrine and metabolic disorders.
MBX (Nasdaq: MBX) completed an End-of-Phase 2 meeting with the FDA and plans to start a randomized Phase 3 trial of once-weekly canvuparatide for chronic hypoparathyroidism in Q3 2026. The Phase 3 design: ~160 patients randomized 3:1, 4-week fixed dose (600 micrograms), 18-week titration, 4-week maintenance, primary analysis at Week 26, then open-label extension. The company also received orphan drug designation from the European Medicines Agency for chronic hypoparathyroidism.
MBX Biosciences (NASDAQ: MBX) completed an End-of-Phase 2 meeting with the FDA and plans to initiate a pivotal Phase 3 trial of once-weekly canvuparatide for chronic hypoparathyroidism in Q3 2026. Key Phase 3 elements are set: ~160 patients randomized 3:1, primary endpoint at Week 26, dose selection, titration schedule, and an open-label extension. The program also received orphan drug designation from the European Medicines Agency, supporting development in Europe.
MBX Biosciences (Nasdaq: MBX) announced that CEO Kent Hawryluk and CMO Sam Azoulay will participate in four Miami investor events in March 2026: Citizens Life Sciences Conference (Mar 10), UBS Biotech Summit (Mar 10), Jefferies Biotech on the Beach (Mar 11) and Barclays Global Healthcare Conference (Mar 11).
Fireside chats are scheduled at Citizens Life Sciences (9:00–9:25 a.m. ET) and Barclays (3:00–3:25 p.m. ET); other meetings are 1x1. Live webcasts and replays will be available on the company website and archived for ~90 days.
MBX Biosciences (Nasdaq: MBX) said CEO Kent Hawryluk and CMO Sam Azoulay will present at two upcoming investor conferences in late Feb–early Mar 2026.
Events: Oppenheimer 36th Annual Healthcare Life Sciences Conference (virtual) on Feb 25, 2026 at 11:20–11:50 a.m. ET, and TD Cowen 46th Annual Health Care Conference in Boston on Mar 2, 2026 at 9:10–9:40 a.m. ET. Live webcasts and replays will be available via the company's events page and archived for about 90 days.
MBX Biosciences (Nasdaq: MBX) appointed Laurie Stelzer as an independent director and chair of the board's audit committee, effective Jan. 22, 2026. Stelzer brings over 25 years of finance and corporate governance experience, including prior CFO roles at Kailera Therapeutics, Orna Therapeutics, Mirati Therapeutics, Arena Pharmaceuticals, and Halozyme Therapeutics, and board service at multiple biotech companies. The company said the appointment strengthens financial oversight as MBX advances a catalyst-rich year that includes data from three clinical-stage programs and initiation of a Phase 3 confirmatory trial in hypoparathyroidism.
MBX Biosciences (Nasdaq: MBX) will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan 13, 2026 and provide a 2026 outlook and business update.
Key clinical milestones: one-year follow-up data from the Phase 2 once-weekly canvuparatide expected Q2 2026 with Phase 3 initiation targeted Q3 2026; Phase 1 12-week data for once-monthly potential MBX 4291 expected Q4 2026; two additional obesity candidates nominated in 2026 (amycretin prodrug and GLP-1/GIP/GCGR prodrug). Preliminary unaudited cash and marketable securities were approximately $373.7M as of Dec 31, 2025, expected to fund operations into 2029.
MBX Biosciences (Nasdaq: MBX) announced that Kent Hawryluk, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
Format includes a company presentation and 1x1 meetings at 3:45 p.m. PT / 6:45 p.m. ET in San Francisco. A live webcast will be available via the company’s investor events page, with a replay posted approximately two hours after the events and archived for about 90 days.